Orbimed Advisors LLC Cytom X Therapeutics, Inc. Transaction History

Orbimed Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.41 - $2.74 $5 Million - $9.71 Million	3,544,578 New	3,544,578 $7.73 Million
Q1 2022 May 16, 2022	SELL	$2.67 - $4.68 $2.91 Million - $5.1 Million	-1,089,534 Reduced 33.89%	2,124,975 $5.67 Million
Q4 2021 Feb 14, 2022	BUY	$3.87 - $7.39 $5.39 Million - $10.3 Million	1,392,641 Added 76.44%	3,214,509 $13.9 Million
Q3 2021 Nov 15, 2021	BUY	$4.32 - $6.43 $1.33 Million - $1.98 Million	308,700 Added 20.4%	1,821,868 $9.27 Million
Q2 2021 Aug 16, 2021	BUY	$6.33 - $9.91 $9.58 Million - $15 Million	1,513,168 New	1,513,168 $9.58 Million

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.